ankyrin repeat and SOCS box containing 13Genealiases: []
Q-omics provides the consensus-scored ASB13 profile across patient tissues and cancer cell-line models. ASB13 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ASB13 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ASB13 RNA expression shows 19,215 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where ASB13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASB13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASB13 survival associations across molecular data types. ASB13 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASB13 RNA expression–survival associations across cancer types. High ASB13 expression shows favorable associations in KIRC, KIRP, HNSC, LGG, READ and STAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ASB13 RNA expression.
This table summarizes ASB13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ASB13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASB13 shows lower tumor expression in KICH, THCA and KIRP and higher tumor expression in KIRC, STAD and BRCA. The KICH box plot shows higher ASB13 RNA expression in normal versus tumor tissue (log2 FC = −1.985, t-test p < 0.001).
This table shows molecular features associated with ASB13 in patient tissues and cancer cell lines. In patient samples, ASB13 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ASB13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Lymphoma.
